Skip to main content

Colesevelam (Monograph)

Brand name: WelChol
Drug class: Bile Acid Sequestrants
VA class: CV350
Chemical name: 2-Propen-1-amine polymer withN,N,N-trimethyl-6-(2-propenylamino)-1-hexanaminium chloride-(chloromethyl)oxirane and N-2-propenyl-1-decanamine hydrochloride
Molecular formula: (C3H7N)m(C3H5ClO)n(C12H27ClN2)o(C13H27N)pxHCl
CAS number: 182815-44-7

Medically reviewed by Drugs.com on Jul 17, 2023. Written by ASHP.

Introduction

Antilipemic agent (bile acid sequestrant). Adjunct antidiabetic agent for type 2 diabetes mellitus.

Uses for Colesevelam

Primary Hypercholesterolemia

Adjunct to dietary therapy and exercise to decrease elevated serum LDL-cholesterol concentrations in the management of primary hypercholesterolemia (Frederickson type IIa).

May be used alone or combined with a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (i.e., statin).

Effect of colesevelam (alone or in combination with a statin) on cardiovascular morbidity and mortality not established.

Safety and efficacy of colesevelam for management of Fredrickson type I, III, IV, and V dyslipidemias [off-label] not established. (See Hypertriglyceridemia under Cautions.)

AHA/ACC cholesterol management guideline states that lifestyle modification is the foundation of cardiovascular risk reduction. If pharmacologic therapy is needed, statins are first-line drugs of choice because of their demonstrated benefits in reducing risk of atherosclerotic cardiovascular disease (ASCVD). The addition of a nonstatin drug (e.g., ezetimibe, bile acid sequestrants, PCSK9 inhibitor) may be considered in certain circumstances such as in patients with very severe elevations of LDL-cholesterol concentrations who are not achieving adequate LDL lowering with maximally tolerated statin therapy.

Diabetes Mellitus

Used in combination with metformin, sulfonylurea, or insulin monotherapy or in combinations with these and other oral antidiabetic agents as an adjunct to diet and exercise for the management of type 2 diabetes mellitus.

Safety and efficacy as monotherapy or in combination with a dipeptidyl peptidase-4 (DPP-4) inhibitor not established in type 2 diabetes mellitus; has not been studied extensively in combination with thiazolidinediones.

Not effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis.

Colesevelam Dosage and Administration

General

Monitoring during Antilipemic Therapy

Administration

Oral Administration

Administer orally once or twice daily with a liquid at mealtime.

May be administered simultaneously with a statin.

Drugs known to interact with colesevelam or drugs that have not been evaluated in formal drug interaction studies with colesevelam, especially those with a narrow therapeutic index, (see Interactions), should be administered at least 4 hours prior to colesevelam. Alternatively, monitor blood concentrations of the co-administered drug.

Dosage

Available as colesevelam hydrochloride; dosage expressed in terms of colesevelam.

Adults

Dyslipidemias
Primary Hypercholesterolemia
Oral

Initially, 1.875 g (3 tablets) twice daily or 3.75 g (6 tablets) once daily. May increase dosage to 4.375 g (7 tablets) daily depending on desired therapeutic effect.

Diabetes Mellitus

Oral: 1.875 g (3 tablets) twice daily or 3.75 g (6 tablets) once daily in combination with other antidiabetic agents (e.g., metformin, a sulfonylurea, insulin) in patients with type 2 diabetes mellitus.

Therapeutic response usually occurs following 4–6 weeks of treatment and reaches maximal or near maximal after 12–18 weeks of therapy.

Cautions for Colesevelam

Contraindications

Warnings/Precautions

General Precautions

Hypertriglyceridemia

Increased serum triglyceride concentrations reported in patients with primary hypercholesterolemia or type 2 diabetes mellitus (particularly patients receiving concomitant insulin or sulfonylurea therapy). Severe hypertriglyceridemia can cause pancreatitis.

Not systematically studied in patients with triglyceride concentrations >300 mg/dL. Use with caution in patients with baseline triglyceride concentrations of 250–299 mg/dL; monitor lipoprotein concentrations periodically during therapy. Manufacturer recommends discontinuing therapy if serum triglyceride concentrations exceed 500 mg/dL or if hypertriglyceridemia-induced pancreatitis occurs.

Fat-soluble Vitamin Deficiency

Bile acid sequestrants may decrease absorption of fat-soluble vitamins A, D, E, and K. Effects of colesevelam on co-administered dietary or supplemental vitamin therapy, including such use in pregnant women, not established.

Hemorrhage from vitamin K deficiency reported in rats receiving relatively high doses (30 times the usual human dosage). Clinically important effects on absorption of fat-soluble vitamins not observed in clinical trials. Use caution in patients susceptible to vitamin K deficiency (e.g., concomitant warfarin therapy, malabsorption syndromes) or other fat-soluble vitamin deficiency. (See Interactions.)

GI Disorders

Large tablet size of colesevelam may cause dysphagia or esophageal obstruction; use caution in patients with dysphagia or swallowing disorders.

Not recommended in patients with gastroparesis, other GI motility disorders, or those who have undergone major GI tract surgery and who may be at risk for bowel obstruction.

Combination Therapy

When used in combination with metformin, a sulfonylurea, or insulin, consider the cautions, precautions, and contraindications associated with the concomitant agent(s).

Specific Populations

Pregnancy

Category B.

Requirements for vitamins and other nutrients increased during pregnancy. (See Fat-soluble Vitamin Deficiency under Cautions.)

Lactation

Colesevelam is not expected to distribute into milk.

Pediatric Use

Safety and efficacy not established in children <18 years of age. Not recommended in pediatric patients because of large tablet size.

Geriatric Use

No overall differences in safety and efficacy relative to younger adults, but increased sensitivity cannot be ruled out.

Renal Impairment

In patients with type 2 diabetes mellitus, no overall differences in safety or efficacy observed between patients with moderate renal insufficiency (Clcr <50 mL/minute) and those with mild renal insufficiency (Clcr ≥50 mL/minute).

Common Adverse Effects

Patients with primary hypercholesterolemia: Constipation, dyspepsia, nausea, accidental injury, asthenia, pharyngitis, flu-like syndrome, rhinitis, myalgia.

Patients with type 2 diabetes mellitus: Constipation, nasopharyngitis, dyspepsia, hypoglycemia, nausea, hypertension.

Drug Interactions

If administered with a drug with a narrow therapeutic index (i.e., alterations in blood concentrations associated with clinically important effect on efficacy and/or safety) that has not been evaluated in formal drug interaction studies, administer drug at least 4 hours prior to colesevelam, or consider monitoring drug concentrations.

Increased serum triglyceride concentrations observed in clinical studies with concomitant sulfonylurea or insulin therapy.

Specific Drugs

Drug

Interaction

Comments

Cephalexin

Pharmacokinetic interaction unlikely

Ciprofloxacin

Pharmacokinetic interaction unlikely

Digoxin

Pharmacokinetic interaction unlikely

Fat-soluble vitamins (i.e., vitamins A, D, E, K)

Potential decreased absorption of fat-soluble vitamins A, D, E, K (see Fat-soluble Vitamin Deficiency under Cautions)

Administer at least 4 hours prior to colesevelam

Fenofibrate

Additive effects in reducing total and LDL cholesterol

HMG-CoA reductase inhibitors (statins)

Additive antilipemic effects

Lovastatin: Pharmacokinetic interaction unlikely

Used to therapeutic advantage

Glyburide

Potential decreased peak plasma concentration and AUC of glyburide

Administer at least 4 hours prior to colesevelam

Metoprolol

Pharmacokinetic interaction unlikely

Quinidine

Pharmacokinetic interaction unlikely

Oral contraceptives (ethinyl estradiol combined with norethindrone)

Decreased peak blood concentrations of ethinyl estradiol and norethindrone, decreased AUC of ethinyl estradiol

Administer at least 4 hours prior to colesevelam

Phenytoin

Potential decreased blood phenytoin concentrations; potential for increased seizure activity

Administer at least 4 hours prior to colesevelam

Thyroid agents (e.g., levothyroxine)

Increased TSH concentrations; decreased peak blood levothyroxine concentrations and AUC

Administer at least 4 hours prior to colesevelam

Valproic acid

Pharmacokinetic interaction unlikely

Verapamil (extended-release)

Pharmacokinetic interaction unlikely

Warfarin

Potential reduced INR; pharmacokinetic interaction unlikely

Monitor INR prior to colesevelam therapy and subsequently to ensure no appreciable alteration in INR; once INR is stable, monitor periodically at recommended intervals for warfarin therapy

Colesevelam Pharmacokinetics

Absorption

Bioavailability

Not absorbed from the GI tract.

Onset

Maximum therapeutic response usually occurs within 2 weeks and is maintained during long-term (≥50 weeks) therapy.

Elimination

Elimination Route

Binds to bile acids in the intestine and forms a nonabsorbable complex that is excreted in feces.

Stability

Storage

Oral

Tablets

25°C (may be exposed to 15–30°C). Protect from moisture.

Actions

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Colesevelam Hydrochloride

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

625 mg

WelChol

Daiichi Sankyo

AHFS DI Essentials™. © Copyright 2024, Selected Revisions July 26, 2021. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

Reload page with references included